8-KEarnings & ResultsExhibits & Filings

Elevance Health, Inc. 8-K Report, Financial Results (Jan 26, 2022)

Filed January 26, 2022For Securities:ELV

Summary

Elevance Health, Inc. (formerly Anthem, Inc.) filed an 8-K on January 26, 2022, to furnish a press release detailing its financial results for the quarter ended December 31, 2021. This filing primarily serves to publicly disseminate these results, which were announced via a press release incorporated as an exhibit. Investors should note that this information, while important for understanding recent performance, is furnished and not formally filed, meaning it carries less regulatory weight under Section 18 of the Exchange Act. The report also includes standard forward-looking statements and risk factor disclosures relevant to the company's operations and the broader healthcare industry. While the 8-K itself doesn't contain new operational data beyond what's in the press release, it signals the company's proactive communication of its financial performance to the market. Investors are advised to review the accompanying press release (Exhibit 99.1) for specific details on earnings, revenue, and any management commentary regarding the company's outlook and strategic initiatives. The inclusion of forward-looking statements and a comprehensive list of risks underscores the inherent uncertainties in the healthcare sector, including impacts from the pandemic, regulatory changes, and competitive pressures.

Key Highlights

  • 1Elevance Health (formerly Anthem) announced its Q4 2021 financial results via an 8-K filing, incorporating a press release (Exhibit 99.1).
  • 2The filing's primary purpose is to make the Q4 2021 earnings report publicly available.
  • 3Information furnished in the 8-K and press release is not deemed 'filed' for Section 18 purposes, limiting its regulatory liability.
  • 4The report includes standard forward-looking statements, cautioning investors about future projections and potential risks.
  • 5Key risks highlighted include the impact of public health emergencies (like COVID-19), healthcare cost trends, regulatory changes (ACA), and competitive pressures.
  • 6Risks related to the company's PBM business and cybersecurity are also mentioned.
  • 7Investors are directed to the press release (Exhibit 99.1) for specific financial performance details for the quarter ended December 31, 2021.

Frequently Asked Questions

The main purpose of this 8-K filing is to publicly disseminate Elevance Health's financial results for the quarter ended December 31, 2021, through an accompanying press release (Exhibit 99.1).

No, this 8-K filing primarily incorporates by reference a press release that contains the financial results. Investors should refer to Exhibit 99.1 for the specific financial details and commentary.

No, the information furnished in Item 2.02 and Exhibit 99.1 is explicitly stated as not being 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934. This means the company has limited legal liability for the accuracy of this furnished information compared to information formally filed.

The filing highlights several risks, including the impact of large-scale medical emergencies like COVID-19, rising healthcare costs, regulatory changes (especially concerning the ACA), competitive pressures within the healthcare industry, and risks associated with its pharmacy benefit management (PBM) business and cybersecurity.